Literature DB >> 19463462

Percutaneous device closure of patent foramen ovale in patients with presumed cryptogenic stroke or transient ischemic attack: the Mayo Clinic experience.

Monique A Ford1, Guy S Reeder, Ryan J Lennon, Robert D Brown, George W Petty, Allison K Cabalka, Frank Cetta, Donald J Hagler.   

Abstract

OBJECTIVES: We sought to determine safety, recurrence rates, and novel risk factors for recurrence in patients with cryptogenic stroke/transient ischemic attack (TIA) after patent foramen ovale closure.
BACKGROUND: Patent foramen ovale closure in patients with cryptogenic stroke/TIA remains highly controversial. There are limited data on long-term recurrence rates and their predictors in these patients.
METHODS: The records of all patients who underwent patent foramen ovale device closure between December 2001 and June 2006 were reviewed. Patients were seen for clinical follow-up at 3 months then followed annually via telephone. Primary end points were recurrent stroke/TIA. Kaplan-Meier methods were used to estimate recurrent event rates. Cox regression analysis was used to identify risk factors for recurrences.
RESULTS: There were 352 patients with cryptogenic stroke (n = 225) or TIA (n = 118) with a mean age of 53.4 years. The procedural complication rate was 3.4%. Recurrent events occurred in 8 patients: 7 strokes and 2 TIA, 1 patient had 2 recurrent strokes. The recurrence rate was 0.6% and 2.1% for stroke and 0.3% and 0.7% for TIA at 1 and 4 years, respectively. The combined end point of recurrent stroke/TIA occurred at a rate of 0.9% and 2.8% at 1 and 4 years, respectively. Risk factors for recurrences were elevated pulmonary artery pressure (hazard ratio [HR]: 1.12, p = 0.009), elevated right ventricular pressure (HR: 1.09, p = 0.04), factor V Leiden mutation (HR: 7.42, p = 0.014), and protein S deficiency (HR: 12.2, p = 0.002). Residual shunt and atrial septal aneurysm were not associated with recurrences.
CONCLUSIONS: Patent foramen ovale device closure is safe and is associated with a low recurrence of stroke/TIA. Factors associated with recurrence are thrombophilia and elevated intracardiac pressures.

Entities:  

Mesh:

Year:  2009        PMID: 19463462     DOI: 10.1016/j.jcin.2008.12.015

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  5 in total

1.  Long-term results of the amplatzer cribriform occluder for patent foramen ovale with associated atrial septal aneurysm: impact on occlusion rate and left atrial functional remodelling.

Authors:  Gianluca Rigatelli; Fabio Dell'avvocata; Paolo Cardaioli; Gabriele Braggion; Massimo Giordan; Alberto Mazza; Chiara Fraccaro; Mauro Chinaglia; Jack P Chen
Journal:  Am J Cardiovasc Dis       Date:  2011-12-15

2.  PFO closuRE and CryptogenIc StrokE (PRECISE) registry: a multi-center, international registry.

Authors:  Jochen Wöhrle; Bernard Bertrand; Lars Søndergaard; Mark Turner; Werner Scholtz; Réda Ibrahim; François Bourlon
Journal:  Clin Res Cardiol       Date:  2012-04-10       Impact factor: 5.460

Review 3.  Transcatheter Patent Foramen Ovale Closure in Stroke Patients with Thrombophilia: Current Status and Future Perspectives.

Authors:  Julio I Farjat-Pasos; Jorge Nuche; Jules Mesnier; Vassili Panagides; Stephanie Cloutier; Christine Houde; Josep Rodés-Cabau
Journal:  J Stroke       Date:  2022-09-30       Impact factor: 8.632

Review 4.  Atrial septal defects - clinical manifestations, echo assessment, and intervention.

Authors:  Seth S Martin; Edward P Shapiro; Monica Mukherjee
Journal:  Clin Med Insights Cardiol       Date:  2015-03-23

5.  Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta-analysis of randomized clinical trials.

Authors:  Irbaz Bin Riaz; Abhijeet Dhoble; Ahmad Mizyed; Chiu-Hsieh Hsu; Muhammad Husnain; Justin Z Lee; Kapildeo Lotun; Kwan S Lee
Journal:  BMC Cardiovasc Disord       Date:  2013-12-11       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.